Market Place
Sourcing Support
Ensoma Initiates Phase 1/2 Trial For EN-374 In X-CGD
01 Dec 2025 //
BUSINESSWIRE
Fierce Biotech Layoff Tracker 2025: Ensoma, Applied Tx & More
21 Nov 2025 //
FIERCE BIOTECH
Genetic Medicines Biotech Halves Team
20 Nov 2025 //
FIERCE BIOTECH
Ensoma Shows In Vivo HSC-Derived CAR-M/NK/T Platform Data
04 Nov 2025 //
BUSINESSWIRE
Ensoma To Present Preclinical Data At SITC 2025
03 Oct 2025 //
BUSINESSWIRE
Ensoma Raises $53M for EN-374, In Vivo Stem Cell Pipeline
22 Sep 2025 //
BUSINESSWIRE
Ensoma`s FDA Clears IND for First In Vivo HSC Gene Therapy
12 May 2025 //
BUSINESSWIRE
Ensoma to Present Data & Advancements at ASGCT Meeting
29 Apr 2025 //
BUSINESSWIRE
Ensoma Receives Pediatric & Orphan Designations for EN-374 in CGD
13 Feb 2025 //
BUSINESSWIRE
Ensoma Unveils Programs in Genetic, Immune & Oncological Diseases
05 Nov 2024 //
BUSINESSWIRE
Ensoma Appoints Jon Garen Chief Corp Dev and Business Officer
28 Oct 2024 //
BUSINESSWIRE
Ensoma shutters Copenhagen site from its Twelve Bio acquisition
30 Sep 2024 //
ENDPTS
Ensoma Appoints Jim Burns, Ph.D. As Chief Executive Officer
13 May 2024 //
BUSINESSWIRE
Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
16 May 2023 //
BUSINESSWIRE
Ensoma Announces Closing of Twelve Bio Acquisition
09 Feb 2023 //
BUSINESSWIRE
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio
05 Jan 2023 //
BIOSPACE
Ensoma Strengthens Scientific Advisory Board
28 Oct 2021 //
BUSINESSWIRE
J&J science chief Stoffels latest exec to exit—Chutes & Ladders
15 Oct 2021 //
FIERCEBIOTECH
Ensoma nabs Bayer`s $1B Parkinson`s head Nuwaysir for gene meds
12 Oct 2021 //
FIERCEBIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.